Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lu...
Biocept, Inc. is a molecular diagnostics compan...
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting ...
Integra LifeSciences, a world leader in medical...
Carie Health is a mobile healthcare solution that allows members to connect with a...
Carie Health is a mobile healthcare solution th...
Altimmune is a clinical-stage immunotherapeutics company focused on the developmen...
Altimmune is a clinical-stage immunotherapeutic...
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on devel...
Jaguar Health, Inc. is a commercial stage pharm...
Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and develop...
Aptinyx Inc. is a clinical-stage biopharmaceuti...
ContraFect is a clinical-stage biotechnology company focused on discovering and de...
ContraFect is a clinical-stage biotechnology co...
Join the National Investor Network and get the latest information with your interests in mind.